These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22607765)

  • 21. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer.
    Jain VK; Hawkes EA; Cunningham D
    Clin Colorectal Cancer; 2011 Dec; 10(4):245-57. PubMed ID: 21729675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapeutic approaches to the treatment of metastatic breast cancer.
    Fernández Y; Cueva J; Palomo AG; Ramos M; de Juan A; Calvo L; García-Mata J; García-Teijido P; Peláez I; García-Estévez L
    Cancer Treat Rev; 2010 Feb; 36(1):33-42. PubMed ID: 19883980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extending survival with chemotherapy in metastatic breast cancer.
    O'Shaughnessy J
    Oncologist; 2005; 10 Suppl 3():20-9. PubMed ID: 16368868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lapatinib in the treatment of HER-2 overexpressing breast cancer.
    Vrdoljak E; Boban M; Ban M
    J BUON; 2011; 16(3):393-9. PubMed ID: 22006739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line chemotherapy with or without biologic agents for metastatic breast cancer.
    Andreetta C; Minisini AM; Miscoria M; Puglisi F
    Crit Rev Oncol Hematol; 2010 Nov; 76(2):99-111. PubMed ID: 20097088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Targeted based therapies in metastatic breast cancer: future evolution].
    Belmondo L; Montana M; Curti C; Crozet M; Rathelot P; Penot-Ragon C; Vanelle P
    Therapie; 2012; 67(6):491-503. PubMed ID: 23249575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N; Swain S
    Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines.
    Comen EA; Fornier MN
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S7-19. PubMed ID: 20805067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies in breast cancer.
    Tripathy D
    Breast J; 2005; 11 Suppl 1():S30-5. PubMed ID: 15725114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.
    El Saghir NS; Tfayli A; Hatoum HA; Nachef Z; Dinh P; Awada A
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):433-49. PubMed ID: 21330148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
    Tsakonas G; Kosmas C
    J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
    Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
    Gligorov J; Lotz JP
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
    Bishop MR
    Haematologica; 2004 May; 89(5):599-605. PubMed ID: 15136224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.